MaaT Pharma has reported positive results from an interim safety analysis of its Phase IIb trial of MaaT033 in subjects ...

LifeMine Therapeutics has dosed the first subject in the Phase I trial of calcineurin inhibitor (CNi), LIFE-001.

Agitated patients are often prescribed antipsychotic medications and sedatives off-label, but this can pose a risk to the ...

Scientist.com has launched a new tool, Clinical Labs Navigator, for sourcing, managing, and executing services for clinical ...

Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS) from the HERCULES trial and in ...

After dropping the FNAIT therapy, Rallybio will prioritise another candidate that is being investigated in complement-driven diseases.

Apnimed has dosed the first subject in the Phase IIA RESTEADY trial of SASS-001, an oral drug combo for sleep apnoea with a ...

US President Donald Trump told reporters last week that pharma tariffs are coming “sometime in the near future”.

J&J exhibited additional findings, displaying that nipocalimab met its key secondary endpoint, a change in QMG score.

The UK Government has announced a £600m ($764m) funding pot to create a new Health Data Research Service, reducing red tape ...

The FDA has granted clearance to CureVac's IND for the open-label Phase I trial of CVHNLC in individuals with sqNSCLC.

AstraZeneca recently announced positive toplined interim results from SERENA-6, a randomised, multicentre, double-blind Phase ...